SeqLL Inc. Announces Pricing of $1.8 Million Registered Direct Offering
February 13 2023 - 8:30AM
SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a
technology company providing life sciences instrumentation and
research services, today announced that it has entered into a
securities purchase agreement (the “Agreement”) with institutional
investors to purchase 2,000,000 of its shares of common stock at a
purchase price of $0.90 per share of common stock in a registered
direct offering (the “Offering”). The gross proceeds to the Company
from the Offering are estimated to be approximately $1.8 million
before deducting the placement agent’s fees and other Offering
expenses.
Maxim Group LLC is acting as the sole placement agent in
connection with the Offering. The Offering is expected to close on
or about February 15, 2023, subject to the satisfaction of
customary closing conditions.
The securities described above are being offered pursuant to the
Company’s shelf registration statement on Form S-3 (File No.
333-268319), which was declared effective by the U.S. Securities
and Exchange Commission (the "SEC") on December 8, 2022. The
Offering will be made only by means of a prospectus supplement that
forms a part of such registration statement. A prospectus
supplement relating to the securities will be filed by the Company
with the SEC. When available, copies of the prospectus supplement
relating to the Offering, together with the accompanying
prospectus, can be obtained at the SEC's website at www.sec.gov or
from Maxim Group LLC, 300 Park Avenue, New York, NY 10022,
Attention: Syndicate Department, or via email at
syndicate@maximgrp.com or telephone at (212) 895-3745.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sales of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such jurisdiction.
About SeqLL Inc. SeqLL is a technology company
providing life sciences instrumentation and research services in
collaborative partnerships aimed at the development of novel
scientific assets and intellectual property across multiple “omics”
fields. The Company leverages its expertise with its True Single
Molecule Sequencing (“tSMS®”) platform to empower scientists and
researchers with improved genetic tools to better understand the
molecular mechanisms of disease that is essential to the continued
development of new breakthroughs in genomic medicine, and that
hopefully address the critical concerns involved with today’s
precision medicine. In sum, our experienced team works with our
collaborators to develop innovative solutions tailored to the needs
of each specific project.
Forward Looking StatementsThis press release
contains certain forward-looking statements, including those
related to the applicability and viability of the
Company’s technology for quantifying RNA molecules from
blood and other statements that are predictive in nature and
those related to regaining compliance with Nasdaq’s continued
listing requirements, and timing and effect thereof.
Forward-looking statements are based on the Company’s current
expectations and assumptions. The Private Securities Litigation
Reform Act of 1995 provides a safe-harbor for forward-looking
statements. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. Prospective investors
are cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this presentation.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements are set forth in the Company’s filings
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the year ended December 31, 2021 under the
caption “Risk Factors.”
Contacts:
John W. Kennedy Investor Relations Tel: +1
(914) 727-7764Email: jwkennedy@seqll.com
SeqLL (NASDAQ:SQL)
Historical Stock Chart
From Mar 2024 to Apr 2024
SeqLL (NASDAQ:SQL)
Historical Stock Chart
From Apr 2023 to Apr 2024